Targeted delivery of etoposide to osteosarcoma cells using poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles

Creative Commons License

Alp E., Cirak T., DEMİRBİLEK M., TÜRK M., GÜVEN E.

TURKISH JOURNAL OF BIOLOGY, cilt.41, sa.5, ss.719-733, 2017 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.3906/biy-1612-17
  • Dergi Adı: TURKISH JOURNAL OF BIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.719-733
  • Anahtar Kelimeler: PHBV nanoparticle, folate targeting, etoposide, targeted drug delivery, osteosarcoma, CANCER-THERAPY, PROTEIN ADSORPTION, DRUG-RELEASE, MICROPARTICLES, APOPTOSIS, ASSAY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Folic acid (FA)-functionalized poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles were prepared to enhance the delivery efficiency of the anticancer drug etoposide for the clinical treatment of osteosarcoma. PHBV nanoparticles were synthesized by emulsification/solvent evaporation technique and obtained in the size range of 200-250 nm and zeta potential range of -21 and -27 mV. Encapsulation efficiency and in vitro drug release were studied. The cytotoxic, apoptotic, and necrotic effects of PHBV nanoparticles were also investigated using Saos-2 osteosarcoma cells. The results obtained in this study demonstrate that etoposide-loaded and FA-functionalized PHBV nanoparticles can be successfully used for targeted treatment of osteosarcoma.